AstraZeneca vs Bank of America: Founders, CEOs and History

Company facts

Founders

CEOs and their tenures

Timeline: AstraZeneca and Bank of America side by side

1. 1904Bank of America

   Bank of Italy Founded

   A.P. Giannini founded the Bank of Italy in San Francisco to expand access to banking for immigrants, wage earners, and small merchants.

2. 1906Bank of America

   San Francisco Earthquake Response

   After the 1906 earthquake, Giannini resumed lending while much of San Francisco's banking system was disrupted. The response turned emergency access to credit into lasting customer trust and became a defining story in the bank's retail identity.

3. 1913AstraZeneca

   Astra AB Founded in Södertälje, Sweden

   400 doctors and apothecaries establish Astra AB to manufacture pharmaceuticals for the Swedish market, creating the foundation for what would become one of Europe's largest drug companies.

4. 1930Bank of America

   Bank of Italy Renamed Bank of America

   The Bank of Italy changed its name to Bank of America on November 1, 1930. The rebrand reflected a wider consumer and business ambition beyond the original immigrant-community label.

5. 1958Bank of America

   BankAmericard Introduced

   Bank of America introduced BankAmericard in 1958, a revolving-credit card that later became part of the Visa system. The product tied the bank to modern consumer credit, merchant acceptance, and payment-network economics.

6. 1993AstraZeneca

   Zeneca Group Spun Off from ICI

   Imperial Chemical Industries demerges its pharmaceuticals and agrochemicals businesses to form Zeneca Group PLC, with initial products including Zestril, Nolvadex, and Zoladex generating approximately $3.2 billion in annual sales.

7. 1998Bank of America

   NationsBank and BankAmerica Merge

   The 1998 merger of Charlotte-based NationsBank and San Francisco's BankAmerica created the first coast-to-coast U.S. bank under the Bank of America name. It also shifted the modern company's headquarters center to Charlotte.

8. 1999AstraZeneca

   Astra and Zeneca Merge to Form AstraZeneca

   The all-share merger of equals completes on 6 April 1999, creating AstraZeneca PLC.

9. 2000AstraZeneca

   Nexium Launch Replaces Prilosec

   AstraZeneca launches Nexium (esomeprazole), the single-isomer successor to Losec/Prilosec, in Europe in 2000 and in the United States in 2001 after FDA approval on 20 February 2001.

10. 2006AstraZeneca

    Acquisition of Cambridge Antibody Technology

    AstraZeneca agrees in May 2006 to buy Cambridge Antibody Technology for 1,320 pence a share, valuing the UK biotech at 702 million pounds or about $1.32 billion.

11. 2006Bank of America

    MBNA Merger Completed

    The MBNA merger expanded the card business to more than 40M active accounts and nearly $140B in managed balances, according to the company's January 2006 release. That size made cards a more important part of consumer banking revenue and risk.

12. 2007AstraZeneca

    Acquisition of MedImmune for $15.6 Billion

    AstraZeneca acquires MedImmune for $15.6 billion, entering the biologics market and gaining the Synagis respiratory syncytial virus franchise and antibody technology platforms. The Gaithersburg facility becomes one of three global R&D centres.

13. 2008Bank of America

    Countrywide Acquisition Approved

    The Federal Reserve approved Bank of America's acquisition of Countrywide in June 2008. The deal added mortgage scale but later became a costly warning about buying distressed loan portfolios during a housing crisis.

14. 2008Bank of America

    Merrill Lynch Acquisition Approved

    The Federal Reserve approved the acquisition of Merrill Lynch in November 2008. Although the integration was controversial, Merrill became central to the company's wealth-management and investment-banking fee base.

15. 2012AstraZeneca

    Pascal Soriot Appointed CEO

    Pascal Soriot joins AstraZeneca as Chief Executive Officer on October 1, 2012, with a base salary of $1.4 million and a mandate to reverse declining revenue and R&D productivity through science-led investment.

16. 2014AstraZeneca

    Pfizer Hostile Takeover Rejected

    AstraZeneca's board rejects a $117 billion hostile takeover offer from Pfizer, with Soriot arguing that the undervaluation would destroy long-term shareholder value and pipeline potential.

17. 2014AstraZeneca

    Acquisition of Almirall Respiratory Portfolio

    AstraZeneca acquires the respiratory portfolio of Spanish pharmaceutical company Almirall for approximately $2.1 billion, strengthening the company's position in COPD and asthma with products including Eklira and pipeline candidates that become Breztri.

18. 2014Bank of America

    Mortgage Settlements With the Justice Department and FHFA

    Bank of America agreed in August 2014 to a $16.65B settlement with the Justice Department over mortgage claims tied to Countrywide and Merrill Lynch, following a March 2014 FHFA agreement with an aggregate payment of about $9.33B.

19. 2015AstraZeneca

    Tagrisso Approved for EGFR-Mutated Lung Cancer

    The FDA approves Tagrisso (osimertinib) in November 2015 for metastatic EGFR T790M mutation-positive non-small cell lung cancer, the first product from Soriot's reinvestment strategy to reach market.

20. 2017AstraZeneca

    Imfinzi Approved Based on PACIFIC Trial

    The FDA approves Imfinzi (durvalumab) for unresectable stage III non-small cell lung cancer after chemoradiation, based on PACIFIC trial data showing survival benefits.

21. 2018Bank of America

    Erica Launched

    Bank of America launched Erica in 2018 as an AI-enabled virtual assistant inside digital banking. The launch mattered because customer service, insights, and routine account tasks were moving from branches and call centers into mobile channels.

22. 2020AstraZeneca

    COVID-19 Vaccine Development with Oxford University

    AstraZeneca partners with the University of Oxford to develop and manufacture the Vaxzevria COVID-19 vaccine, distributing billions of doses globally at nonprofit pricing during the pandemic peak.

23. 2021AstraZeneca

    Acquisition of Alexion Pharmaceuticals for $39 Billion

    AstraZeneca completes the $39 billion acquisition of Alexion on July 21, 2021, entering the rare disease market with Soliris and Ultomiris and creating a dedicated rare disease unit headquartered in Boston.

24. 2023AstraZeneca

    CinCor Pharma Acquired for up to $1.8 Billion

    AstraZeneca agrees on 9 January 2023 to acquire CinCor Pharma for up to $1.8 billion, $26 per share in cash plus a $10 per share contingent value right, to gain baxdrostat, an aldosterone synthase inhibitor for resistant hypertension.

25. 2023Bank of America

    CFPB and OCC Orders on Fees, Rewards and Accounts

    In July 2023 the CFPB ordered Bank of America to pay more than $100M to customers for repeat non-sufficient-funds fees, withheld credit card rewards and unauthorized accounts, plus $90M in CFPB penalties, and the OCC added a $60M penalty.

26. 2024AstraZeneca

    Total Revenue Reaches $54.073 Billion

    AstraZeneca reports Total Revenue of $54.073 billion for fiscal year 2024, an 18% increase at actual rates and 21% at constant exchange rates, with 16 blockbuster medicines, 74 regulatory events, and 24 pipeline progression events.

27. 2024AstraZeneca

    Fusion Pharmaceuticals and Gracell Acquisitions

    AstraZeneca acquires Fusion Pharmaceuticals for $2 billion to access radiopharmaceutical technology and Gracell Biotechnologies for $1.2 billion for cell therapy manufacturing, expanding modality diversity into radiopharmaceuticals and CAR-T.

28. 2025AstraZeneca

    Total Revenue Reaches $58.739 Billion

    AstraZeneca reports Total Revenue of $58.739 billion for fiscal year 2025, an 8% increase at constant exchange rates, with 16 positive Phase III readouts, 43 major market approvals, and a commitment to invest $50 billion in U.S. manufacturing by 2030.

29. 2025AstraZeneca

    EsoBiotec Acquired for Up to $1 Billion

    AstraZeneca acquires Belgian biotech EsoBiotec for up to $1 billion to access in vivo cell therapy technology, eliminating the need for ex vivo manufacturing in CAR-T therapies.

30. 2025AstraZeneca

    $50 Billion US Manufacturing and R&D Commitment

    AstraZeneca announces on 21 July 2025 that it will invest $50 billion in United States manufacturing and research by 2030, including a new Virginia facility later raised to $4.5 billion.

31. 2025Bank of America

    $113.1B FY2025 Revenue

    The company reported $113.1B in total revenue net of interest expense and $30.5B in net income for FY2025. The result showed the combined scale of deposits, wealth management, cards, payments, global banking, and markets.

32. 2025Bank of America

    Co-Presidents Named

    On September 12, 2025 Bank of America named Dean Athanasia and Jim DeMare Co-Presidents and gave Chief Financial Officer Alastair Borthwick the added title of executive vice president.

33. 2026AstraZeneca

    Ordinary Shares Begin Trading on the NYSE

    AstraZeneca ordinary shares start trading on the New York Stock Exchange on 2 February 2026 under the ticker AZN, after the American Depositary Share programme and certain debt securities stopped trading on Nasdaq on 30 January 2026.

34. 2026AstraZeneca

    Baxfendy Approved in the US for Hypertension

    The FDA approves Baxfendy (baxdrostat) in May 2026 as the first aldosterone synthase inhibitor for hypertension, used in combination with other antihypertensives in adults who are not adequately controlled.

35. 2026AstraZeneca

    $15 Billion China Investment Through 2030

    AstraZeneca announces on 29 January 2026 that it will invest $15 billion in China through 2030 to expand manufacturing and research, in a market that is its second largest and about 12% of revenue.

Acquisitions

Questions about AstraZeneca vs Bank of America